GH实时信号 | 通过Getagraph.com最大化利润

购买 94683 min ago

@ $22.28

发出时间: 15 Feb 2024 @ 02:20

回报率: -27.87%

上一信号: Feb 14 - 22:30

上一信号: 出售

回报率: 1.83 %

Live Chart Being Loaded With Signals

Commentary (20 Apr 2024 @ 04:00):

Stats
今日成交量	1.85M
平均成交量	2.00M
市值	1.96B
EPS	$0 ( 2024-02-22 )
下一个收益日期	( $-0.940 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.75
ATR14	$0.0280 (0.17%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-15	Tariq Musa	Sell	249	Restricted Stock Units
2024-04-15	Tariq Musa	Buy	249	Common Stock
2024-04-15	Saia John G.	Buy	7 569	Common Stock
2024-04-15	Saia John G.	Sell	2 701	Common Stock
2024-04-15	Saia John G.	Sell	1 108	Common Stock

INSIDER POWER
-46.43
Last 99 transactions
Buy: 864 284 \| Sell: 2 349 747

音量相关性

長: 0.47 (neutral)

短: 0.86 (strong)

Signal:(63.11) Same movement expected

Guardant Health Inc 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Guardant Health Inc 相关性 - 货币/商品

-0.77
( moderate negative )

-0.75
( moderate negative )

0.00
( neutral )

-0.75
( moderate negative )

-0.22
( neutral )

0.28
( neutral )

Guardant Health Inc 财务报表

Annual	2023
营收:	$563.95M
毛利润:	$336.90M (59.74 %)
EPS:	$-4.28

Q4	2023
营收:	$155.05M
毛利润:	$236.19M (152.33 %)
EPS:	$-1.580

Q3	2023
营收:	$143.03M
毛利润:	$85.42M (59.72 %)
EPS:	$-0.730

Q2	2023
营收:	$137.15M
毛利润:	$83.30M (60.74 %)
EPS:	$-0.670

Financial Reports:

No articles found.

Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.